Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957943 | 0.87 | GCGR (0.30) | — | |
| SCHEMBL6969196 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL6966612 | 0.74 | — | — | |
| SCHEMBL8099901 | 0.72 | CCR2 (0.41) | CCR2CCR5 | |
| SCHEMBL6961212 | 0.71 | HSP90B1 (0.34) | CCR2CCR5 | |
| SCHEMBL6962332 | 0.69 | LOXL2 (0.39) | CCR2CCR5LOXL2 | |
| SCHEMBL6969569 | 0.68 | — | — | |
| Oxalic Acid SCHEMBL6973522 | 0.66 | HSP90B1 (0.31) | CCR2CCR5 | |
| SCHEMBL7083876 | 0.65 | HSD11B1 (0.33) | LOXL2 | |
| SCHEMBL6974384 | 0.63 | HSP90B1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
| EP-0786455-B1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6147097-A | METHOD FOR TREATING AIDS | SHIONOGI & CO., LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-5910506-A | IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC | SHIONOGI & CO., LTD. (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0786455-A1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CCR2 2762/4885CCR5 3291/4885LOXL2 3/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CCR2 2762/4885CCR5 3291/4885LOXL2 3/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CCR2 2762/4885CCR5 3291/4885LOXL2 3/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CCR2 2762/4885CCR5 3291/4885LOXL2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.